Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Juluca

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

- PMLiVE

Gilead and Aelix join forces to pursue HIV ‘cure’

The HTI vaccine could replace antiretroviral therapy if it reaches market

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

Gilead Sciences

Gilead, Galapagos JAK inhibitor clears phase II test

Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

ViiV chalks up another win for two-drug HIV regimen

Once a month injection matches triple oral therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links